Small molecule drug may prevent chemotherapy resistance
Scientists have discovered a small molecule drug that may stop cancer cells from becoming resistant to chemotherapy. Drug resistance is a major cause of cancer relapse and is responsible for as much as 90% of deaths related to the disease.
The new compound, which was tested in an animal model of melanoma, could make current chemotherapies more powerful. It works by thwarting cancer’s ability to survive, evolve, and adapt to the DNA damage created by traditional chemotherapy drugs like cisplatin.
“Chemotherapies are often effective the first time around, but then the cancers mutate and become resistant to that drug, and the next, and the next,” said senior study co-author Pei Zhou, Ph.D., a professor of biochemistry at Duke University School of Medicine.
“It reminds me of Boggarts, those shapeshifting creatures from Harry Potter that morph from one scary thing to another. The beauty of this approach is that you essentially freeze the Boggart in its current form, so you can kill it off for good.”
The study was published June 6 in Cell.
In their simplest form, cancer cells are normal cells that are growing out of control. Each time these cells divide, the DNA within them must replicate to generate new copies to go inside each new cell. The first chemotherapy drugs were based on the rationale that rapidly growing cancer cells would be more sensitive to damage to their DNA. Drugs like cisplatin are designed to damage DNA, causing the sensitive replication machinery normally tasked with copying each strand to stall. If DNA replication is stalled for too long, cell division halts, and cells die.
The strategy is brutal and effective, even curative in some cases. But long-term, it often fails, as cancer cells figure out a way to proliferate even in the presence of DNA damage.
“The cancer cells often swap out the high fidelity replication machinery, which usually does the copying, with a sloppy replacement that covers up the lesions and moves on,” said Zhou. “As a result, the cells survive, but with mutations in their DNA.”
Because this process, known as translesion synthesis, is a major cause of cancer drug resistance, it has become a major area of study in cancer research. Scientists have identified a key protein involved, named Rev1, and have even disrupted it through genetic means — works done in the laboratories of Graham C. Walker and Michael T. Hemann at MIT, both senior co-authors of this study. However, attempts to do the same with small molecules had never succeeded, presumably because the protein lacked an obvious binding pocket that a potential drug could exploit.
In this study, Zhou and his collaborators at Duke, MIT, and the University of Rhode Island decided to try their luck at finding a small molecule to block or inhibit Rev1. They screened 10,000 small molecule compounds, and were surprised to find that one — a molecule called JH-RE-06 — appeared to do the trick.
The researchers used a technique called x-ray crystallography to visualize the unexpected interactions between Rev1 and JH-RE-06. They found that when Rev1 interacts with JH-RE-06, it pairs up or dimerizes with another copy of itself, creating a binding pocket where there wasn’t one before. When Rev1 is locked up in this dimer, it can no longer help cancer cells survive and attain their shape-shifting powers.
The researchers then tested the new molecule in human cancer cell lines and showed that it enhanced the ability of several forms of chemotherapy to kill cells, while also suppressing their ability to mutate in the presence of DNA-damaging drugs. Finally, they tested it in a mouse model of human melanoma. They found that not only did the tumors stop growing in mice treated with a combination of cisplatin and JH-RE-06, but also that those mice survived longer.
Senior study co-author Jiyong Hong, PhD, a professor of chemistry at Duke, said that they are currently creating versions of JH-RE-06 that have enhanced pharmacologic properties that could make it an even more attractive drug. “This is a great proof of principle that it is possible to target this protein, but we have a lot of work to do to turn this lead compound into a viable candidate that we can take to the clinic.”
The Latest on: Cancer drug resistance
via Google News
The Latest on: Cancer drug resistance
- Gene discovery could make cancer therapies more effectiveon June 25, 2019 at 12:55 am
This drop in DBC1 decreased p53 levels, making the cells resistant to p53-mediated apoptosis, a form of controlled cell suicide. Many cancer drugs work by inducing apoptotic cell death. The team ... […]
- Engineered cell evolution may provide a path to reduce chemotherapy resistanceon June 24, 2019 at 9:46 pm
A significant problem when treating cancer patients remains drug resistance, which often causes chemotherapy treatments to ultimately fail. Scientists in recent years have hypothesized that cell-cell ... […]
- How vitamin D helps fight treatment-resistant canceron June 22, 2019 at 3:28 am
Researchers from South Dakota State University, in Brookings, have demonstrated that calcitriol and calcipotriol, two active forms of vitamin D, can block a mechanism that enables cancer cells to ... […]
- Incysus Therapeutics Announces Publication of U.S. Patent for Drug Resistant Immunotherapy (DRI) Technologyon June 20, 2019 at 6:34 pm
has issued U.S. Patent No. 10,322,145 titled “Drug Resistant Immunotherapy for Treatment of a Cancer.” The patent covers the treatment of brain cancer with the combination of certain ... […]
- This body-on-a-chip mimics how organs and cancer cells react to drugson June 19, 2019 at 11:09 am
In another setup, the drug tamoxifen knocked out breast cancer cells, but worked against drug-resistant vulva cancer cells only when administered with the blood pressure medication verapamil. These ... […]
- PAR-4 overcomes chemo-resistance in breast cancer cells by antagonizing cIAP1on June 19, 2019 at 2:38 am
is required for breast cancer recurrence and resistance to chemotherapy. Recent advances in the analysis of apoptotic signalling networks have uncovered an important role for activation of caspase-8 ... […]
- Researchers find possible counterpunch to drug resistance of melanomaon June 19, 2019 at 12:36 am
Researchers at Oregon State University and Oregon Health & Science University have found a possible counterpunch to the drug resistance of melanoma, the most dangerous form of skin cancer. The ... […]
- Researchers relate amplification of chromosomal region with resistance to chemotherapeutic drug in breast canceron June 18, 2019 at 8:35 am
Researchers at the Bellvitge Biomedical Research Institute (IDIBELL), with the participation of collaborators from the Baylor College of Medicine (Houston) and the University Institute of Oncology ... […]
- Multi-Drug Therapies Improve Precision Medicine for Canceron June 17, 2019 at 10:15 am
... drug therapies helped improve outcomes among patients with therapy-resistant cancers, indicating that combination drug treatments could improve precision medicine for cancer care, according to a ... […]
- Promising breast cancer drug could reshape treatmenton June 15, 2019 at 4:23 pm
Women with HER2 can start by taking the breast cancer drug Herceptin, then often move to Kadcyla once the cancer becomes resistant. After the disease overpowers Kadcyla, there is no standard course of ... […]
via Bing News